IL17A-IN-1 

IL17A-IN-1 (compound 72) is an orally active Interleukin 17A inhibitor. IL17A-IN-1 can be used in the study of inflammatory and autoimmune diseases (plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis, etc.), as well as cancer^[1].

IL17A-IN-1 inhibits Hela cells with an IC₅₀ value of 0.005 µM^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

IL17A-IN-1 (10 mg/kg; p.o.; single dose) inhibits plasma CXCL1 secretion in hIL17A-induced mouse (IL17 receptor-containing mouse) CXCL1 PD model^[1]. (Subcutaneous injection of recombinant human IL17A into mice induces plasma CXCL1 secretion).

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

612.55

C₃₀H₃₅Cl₂N₇O₃

CN1CCC(N2CC3=NC([C@H](C)NC([C@@]4(NC(C5=CC(Cl)=C(Cl)N5)=O)C[C@H](OC4)C6=CC=CC=C6)=O)=NC=C3C2)CC1

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Ramos AL, et al. Discovery of Small Molecule Interleukin 17A Inhibitors with Novel Binding Mode and Stoichiometry: Optimization of DNA-Encoded Chemical Library Hits to In Vivo Active Compounds. J Med Chem. 2024 Apr 4.  [Content Brief]